The Swiss Federal Institute of Technology Zurich (ETH) is expanding a rented building in Schlieren for its medical research. The close proximity to partners and some of their spin-offs in the Bio-Technopark Schlieren-Zurich should favor the transfer of results into practice.
ETH is strengthening its medical research and building a new site in Schlieren. A leased building (SSA) is currently being expanded accordingly for this purpose. It is located in the immediate vicinity of the Wagi site and thus of the Bio-Technopark Schlieren-Zurich. It is scheduled to be ready for occupancy in January 2025.
According to a media release, the SSA offers space for eight to ten professorships or research groups in the life sciences on approximately 7,000 square meters. The building will be used "very efficiently and flexibly," as will expensive scientific equipment.
According to the information, this is also intended to promote networking with the various research and industrial companies that maintain sites in the Bio-Technopark. In particular, ETH addresses the University Hospital Zurich, the University of Zurich and the pharmaceutical company Roche. An optimal research environment would also benefit from the close proximity to its medical spin-offs located there, such as Anavo medical, Acytronix or Suri BioTech.
This is because, in addition to basic research, ETH Zurich also contributes to "ensuring that research results reach clinics and patients quickly," Vice President Research Christian Wolfrum is quoted as saying. "Accordingly, it is also investing in translational research." It combines basic research with the practical application of research findings in patient care. mm
You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More Information